Investor Profile: OrbiMed — Thesis, Cheque Size & How to Apply

Founders researching OrbiMed funding should know they are dealing with one of the largest dedicated healthcare investors on the planet. With over $21 billion in assets under management and a team of more than 150 scientific, medical and investment professionals, OrbiMed invests across the entire healthcare industry — from start-ups to large multinational corporations — through private equity, public equity and royalty/credit funds. Fresh off a $3 billion fundraise announced in October 2026, the firm is one of the deepest pools of healthcare capital in the world.

Thesis and focus areas

OrbiMed is healthcare-only. Its stated hunting ground runs from biopharmaceuticals to medical devices, digital health, diagnostics and healthcare services — scouting the globe for innovations that help people live healthier, longer lives. The firm argues the industry sits at the intersection of powerful long-term trends: ageing demographics and relentless scientific innovation in treating disease. Its three strategies are private equity (start-ups through growth equity, typically as a lead investor), public equity (long/short and event-driven funds across publicly traded healthcare companies), and private credit/royalty (non-dilutive structured debt for commercial-stage companies and royalty monetisation). Geographically it invests across North America, Asia and Europe from 12 global locations, including New York, London, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. Impact is part of the pitch: the firm says it has committed over $3 billion to developing-country healthcare, and that its venture-capital portfolio companies have brought 90 new healthcare therapies to patients.

Cheque size and stage

OrbiMed does not publish a standard cheque range, but the shape of its investing is clear: private-equity deals run from seed-stage venture through growth equity, with the firm typically leading rounds and helping build companies into market leaders. The October 2026 raise shows where the firepower sits: OrbiMed Private Investments X raised over $1.9 billion for US and European life-sciences venture opportunities, while OrbiMed Asia Partners VI raised over $1 billion for healthcare growth equity and venture capital across Asia. In 2025 the firm also closed a $1.86 billion royalty and credit fund — its largest to date — giving founders non-dilutive options alongside equity.

Notable portfolio

OrbiMed's portfolio spans more than 500 companies, with over 130 venture-backed IPOs. Companies recently spotlighted by the firm include ADARx (RNA-targeting therapeutics), Treeline Biosciences (oncology drug discovery), Mirador Therapeutics (precision immunology), Insmed (a commercial-stage biopharma with the approved lung-disease therapies ARIKAYCE and BRINSUPRI), Biokin (antibody and ADC oncology therapies), Avenzo Therapeutics (next-generation oncology) and Perfuse Therapeutics, which Bayer agreed to acquire.

Team

OrbiMed is led by 20 partners, supported by more than 150 professionals with expertise spanning company incubation, strategy, operations and finance. Managing partners Carl Gordon and Carter Neild fronted the firm's 2026 fund announcements.

How to apply for funding

OrbiMed does not publish a public pitch-submission portal. The firm positions itself as a capital provider of choice and typically leads rounds, so founders generally engage through the firm's website (orbimed.com) or via a warm introduction through the healthcare and investor networks OrbiMed operates in. Its press materials list a contact line at (212) 739-6400.